Skip NavigationSkip to Content

Frequency of pathogenic germline variants in pediatric medulloblastoma survivors

  1. Author:
    Rees, Donald
    Gianferante, D Matthew
    Kim, Jung
    Stavrou, Theodora
    Reaman, Gregory
    Sapkota, Yadav
    Gramatges, M Monica
    Morton, Lindsay M
    Hudson, Melissa M
    Armstrong, Gregory T
    Freedman, Neal D
    Huang, Wen-Yi
    Diver, W Ryan
    Lori, Adriana
    Luo,Wen
    Hicks,Belynda
    Liu,Jia
    Hutchinson,Amy
    Goldstein, Alisa M
    Mirabello, Lisa
  2. Author Address

    1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Rockville, MD, United States. 2Department of Pediatric Hematology and Oncology, Walter Reed National Military Medical Center, Bethesda, MD, United States. 3Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States. 4Department of Public Health, Ministry of Health, Athens, Greece. 5Division Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, United States. 6Departments of Oncology and Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, United States. 7Division of Hematology and Oncology, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, United States. 8Department of Population Science, American Cancer Society, Atlanta, GA, United States. 9Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
    1. Year: 2024
    2. Epub Date: 2024 08 09
  1. Journal: Frontiers in Oncology
    1. 14
    2. Pages: 1441958
  2. Type of Article: Article
  3. Article Number: 1441958
  1. Abstract:

    Medulloblastoma is the most common malignant brain tumor in children. Most cases are sporadic, but well characterized germline alterations in APC, ELP1, GPR161, PTCH1, SUFU, and TP53 predispose to medulloblastoma. However, knowledge about pathogenic/likely pathogenic (P/LP) variants that predispose to medulloblastoma vary based on genes evaluated, patient demographics, and pathogenicity definitions. Germline exome sequencing was conducted on 160 childhood survivors of medulloblastoma. Analyses focused on rare variants in 239 known cancer susceptibility genes (CSGs). P/LP variants were identified using ClinVar and InterVar. Variants of unknown significance in known medulloblastoma predisposing genes (APC, ELP1, GPR161, PTCH1, SUFU, TP53) were further classified for loss of function variants. We compared the frequency of P/LP variants in cases to that in 1,259 cancer-free adult controls. Twenty cases (12.5%) had a P/LP variant in an autosomal dominant CSG versus 5% in controls (p=1.0 x10-3), and 10 (6.3%) of these were P/LP variants in a known medulloblastoma gene, significantly greater than 0.2% observed in controls (p=1.4x10-8). The CSGs with the most P/LP variants in cases, and significantly higher than controls, were ELP1 (p=3.0x10-4) and SUFU (p=1.4x10-3). Approximately one in eight pediatric medulloblastoma survivors had an autosomal dominant P/LP CSG variant. We confirm several known associated genes and identify novel genes that may be important in medulloblastoma. Copyright © 2024 Rees, Gianferante, Kim, Stavrou, Reaman, Sapkota, Gramatges, Morton, Hudson, Armstrong, Freedman, Huang, Diver, Lori, Luo, Hicks, Liu, Hutchinson, Goldstein and Mirabello.

    See More

External Sources

  1. DOI: 10.3389/fonc.2024.1441958
  2. PMID: 39184053
  3. PMCID: PMC11341988

Library Notes

  1. Fiscal Year: FY2023-2024
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel